Viewing Study NCT00004650


Ignite Creation Date: 2025-12-24 @ 5:16 PM
Ignite Modification Date: 2025-12-29 @ 4:28 PM
Study NCT ID: NCT00004650
Status: COMPLETED
Last Update Posted: 2005-06-24
First Post: 2000-02-24
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase III Randomized Study of the Effect of Postmenopausal Estrogen Replacement Therapy on Alveolar Bone Loss
Sponsor: National Institute of Dental and Craniofacial Research (NIDCR)
Organization:

Study Overview

Official Title: None
Status: COMPLETED
Status Verified Date: 1999-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: OBJECTIVES: I. Quantify periodontal alveolar bone loss rates in postmenopausal women.

II. Evaluate the effects of estrogen on alveolar bone loss rates in these patients.

III. Determine whether changes in periodontal bone mass relate to bone mass changes in other skeletal sites in these patients.
Detailed Description: PROTOCOL OUTLINE: This is a randomized, double-blind, placebo controlled study. Patients are randomly assigned to receive placebo or conjugated estrogens and, if no prior hysterectomy, medroxyprogesterone. Patients also receive calcium supplementation therapy daily for 3 years.

Participants in the placebo group may be removed from study if bone loss exceeds 5% per year.

A study duration of 3 years is anticipated.

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
WUSM-900449 None None View